Subscribe To
Panbela announces clinical trial with moffitt cancer center for phase i/ii program in stk11 mutant non-small cell lung cancer
MINNEAPOLIS, May 22, 2023 (GLOBE NEWSWIRE) — Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics ...
May 22, 2023, 12:15 pm
Hepion pharmaceuticals’ phase 2 ‘altitude-nash’ trial achieves primary and secondary endpoints, including improvement in liver function and multiple nash biomarkers
– Improvements in physiologic liver function and key NASH biomarkers including ALT, ProC3, PiiINP and...
May 22, 2023, 11:00 am
Fat brands to present at ld micro invitational xiii
Presentation on Tuesday, June 6 at 4: 3 0 PM PT LOS ANGELES, May 22, 2023 (GLOBE NEWSWIRE) -- FAT (Fresh. Authentic....
May 22, 2023, 9:00 am
Innovative industrial properties: don't fall in love with its dividend yields
iiPR has plunged by -31.84% YTD and -74.1% since its peak in November 2021, triggered by the unlikely f...
May 22, 2023, 9:00 am
Canadian pacific kansas city is on the right track
Put majestic forests, hockey, southern BBQ and this year's Super Bowl LVii champ in a blender, and you ...
May 22, 2023, 8:49 am
Actelis to present at the ld micro invitational xiii
FREMONT, Calif., May 22, 2023 (GLOBE NEWSWIRE) -- Actelis Networks, Inc. (NASDAQ: ASNS) (“Actelis” or the “Company”), a market leader in cyber...
May 22, 2023, 8:00 am
Wisa technologies, inc. to present at ld micro invitational xiii
BEAVERTON, Ore.--(BUSINESS WIRE)---- $WISA #WISA--WiSA Technologies, Inc. announces participation in the LD Micro Invitational X...
May 22, 2023, 7:00 am
Jpmorgan forecasts nii to increase to about $84 bln after first republic deal
JPMorgan Chase & Co on Monday forecast full-year net interest income, excluding markets outlook, will increase to about $84 billion due to its acquisi...
May 22, 2023, 6:21 am
Nexcella announces positive nxc-201 clinical results at asgct: 100% overall response rate in darzalex-relapsed/refractory al amyloidosis with zero icans in ongoing nexicart-1 phase 1b/2a clinical tria
8 AL Amyloidosis patients relapsed/refractory to DARZALEX®-based regimens were treated with CAR-T NXC-201 100% (8/8) overall response rate and 63% (5...
May 21, 2023, 8:05 pm
Nexcella announces positive nxc-201 clinical results at asgct: 100% overall response rate in darzalex-relapsed/refractory al amyloidosis with zero icans in ongoing nexicart-1 phase 1b/2a clinical tria
8 AL Amyloidosis patients relapsed/refractory to DARZALEX®-based regimens were treated with CAR-T NXC-201 100% (8/8) overall response rate and 63% (5...
May 21, 2023, 8:05 pm
Nexcella announces positive nxc-201 clinical results at asgct: 100% overall response rate in darzalex-relapsed/refractory al amyloidosis with zero icans in ongoing nexicart-1 phase 1b/2a clinical tria
8 AL Amyloidosis patients relapsed/refractory to DARZALEX®-based regimens were treated with CAR-T NXC-201 100% (8/8) overall response rate and 63% (5...
May 21, 2023, 8:05 pm
Nexcella announces positive nxc-201 clinical results at asgct: 100% overall response rate in darzalex-relapsed/refractory al amyloidosis with zero icans in ongoing nexicart-1 phase 1b/2a clinical tria
8 AL Amyloidosis patients relapsed/refractory to DARZALEX®-based regimens were treated with CAR-T NXC-201 100% (8/8) overall response rate and 63% (5...
May 21, 2023, 8:05 pm
Immix biopharma announces positive nxc-201 clinical results at asgct: 100% overall response rate in darzalex-relapsed/refractory al amyloidosis with zero icans in ongoing nexicart-1 phase 1b/2a clinic
8 AL Amyloidosis patients relapsed/refractory to DARZALEX®-based regimens were treated with CAR-T NXC-201 100% (8/8) overall response rate and 63% (5...
May 21, 2023, 8:00 pm
Immix biopharma announces positive nxc-201 clinical results at asgct: 100% overall response rate in darzalex-relapsed/refractory al amyloidosis with zero icans in ongoing nexicart-1 phase 1b/2a clinic
8 AL Amyloidosis patients relapsed/refractory to DARZALEX®-based regimens were treated with CAR-T NXC-201 100% (8/8) overall response rate and 63% (5...
May 21, 2023, 8:00 pm
Immix biopharma announces positive nxc-201 clinical results at asgct: 100% overall response rate in darzalex-relapsed/refractory al amyloidosis with zero icans in ongoing nexicart-1 phase 1b/2a clinic
8 AL Amyloidosis patients relapsed/refractory to DARZALEX®-based regimens were treated with CAR-T NXC-201 100% (8/8) overall response rate and 63% (5...
May 21, 2023, 8:00 pm
Immix biopharma announces positive nxc-201 clinical results at asgct: 100% overall response rate in darzalex-relapsed/refractory al amyloidosis with zero icans in ongoing nexicart-1 phase 1b/2a clinic
8 AL Amyloidosis patients relapsed/refractory to DARZALEX®-based regimens were treated with CAR-T NXC-201 100% (8/8) overall response rate and 63% (5...
May 21, 2023, 8:00 pm
Stock market this week: q4 results, us debt ceiling talks, other factors that could drive equities this week
Stock markets witnessed an unpredictable movement last week mainly driven by Fii inflows quarterly earn...
May 21, 2023, 11:14 am
Huntington ingalls: a deep-value defense stock
Huntington Ingalls Industries is a value stock with an implied 2024 free cash flow yield of almost 10%, benefiting investors with a healthy balance sh...
May 21, 2023, 5:55 am
Sovereign gold bond: price for premature redemption of series viii of sgb 2017-18 due on may 20
The RBI has set up a price for early redemption of Series ViiI of SGB 2017-18. This series was introduc...
May 20, 2023, 11:14 am
Rosen, global investor counsel, encourages allbirds, inc. investors with losses to secure counsel before important deadline in securities class action – bird
NEW YORK, May 19, 2023 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of: (i) Allbirds, Inc. (NASDAQ:...
May 20, 2023, 1:48 am